Orthofix posts investor presentation outlining strategy to drive profitable growth in musculoskeletal care
PUBT · 06/01 20:32
Share
Listen to the news
- Orthofix outlined a push to “drive profitable growth” across spine, therapeutic solutions, limb reconstruction, biologics, and 7D FLASH navigation.
- 2026 guidance: net sales USD 838 million to USD 848 million; adjusted EBITDA USD 90 million to USD 93 million.
- TTM net sales about USD 819 million; TTM adjusted EBITDA about USD 84 million; TTM adjusted gross margin about 71.7%.
- Focused on expanding 7D FLASH placements, positioning it as a zero-radiation spine navigation system with 97.8% radiation reduction.
- Free cash flow trend cited as improving from USD -108 million in 2023 to near breakeven in 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved